REMARKS

A Notice of Appeal is being filed currently herewith. According to the Advisory Action dated 13 December 2007, the Amendment After Final dated 21 November 2007 will be entered upon the filing of this Notice of Appeal.

This Second Amendment After Final is being filed to place the claims in condition for allowance. In this amendment, Claim 1 has been amended to insert the specific proteosome inhibitors found in claims 6-9 and 30.

It is submitted that this amendment does not constitute new matter, and its entry is requested.

In the Advisory Action dated 13 December 2007, the Examiner indicated that claims 6-9 and 30 would be allowable if rewritten in independent form. In response to this indication of allowability of these claims, claim 1 has been amended by incorporating the specific proteosome inhibitors that were set forth in claims 6-9 and 30 that were indicated to be allowable. Since claim 1 recites specific compounds and specific structures, the specification provides a complete written description of these listed proteosome inhibitors. Claims 6-9 and 30 depend from amended claim 1 and similarly recite specific compounds and specific structures. Thus, Applicants submit that claims 1-9 and 27-30 are fully described by the specification and are definite.

In view of the above amendments and remarks, it is believed that the claims satisfy the requirements of the patent statutes and are patentable over the prior art. Reconsideration of the

U.S. Patent Application Serial No. 10/522,706 Second Amendment After Final dated 21 February 2008 Reply to Advisory Action dated 13 December 2007

instant application and early notice of allowance are requested. The Examiner is invited to telephone the undersigned if it is deemed to expedite allowance of the application.

Respectfully submitted, ROTHWELL, FIGG, ERNST & MANBECK, p.c.

By ____/Jeffrey L. Ihnen/

Jeffrey L. Ihnen Registration No. 28,957 Attorney for Applicants 1425 K Street, N.W., Suite 800 Washington, D.C. 20005

Telephone No.: (202) 783-6040 Facsimile No.: (202) 783-6031